{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:07:52Z","timestamp":1788541672850,"version":"build-2803163510"},"reference-count":36,"publisher":"American Society of Hematology","issue":"12","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Outcomes for patients with relapsed\/refractory multiple myeloma (R\/RMM) have dramatically improved after the development and now growing utilization of B-cell maturation antigen\u2013targeted chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy. However, health care utilization as a quality-of-life metric in these growing populations has not been thoroughly evaluated. We performed a retrospective cohort study evaluating the frequency and cause of unscheduled health care interactions (UHIs) among patients with R\/RMM responding to B-cell maturation antigen\u2013targeted BsAb and CAR T-cell therapies (N\u00a0= 46). This included the analysis of remote UHIs including calls to physicians\u2019 offices and messages sent through an online patient portal. Our results showed that nearly all patients with R\/RMM (89%) receiving these therapies required a UHI during the first 125\u00a0days of treatment, with a mean of 3.7 UHIs per patient. Patients with R\/RMM responding to BsAbs were significantly more likely to remotely contact their physicians\u2019 offices (1.8-fold increase; P\u00a0= .038) or visit an urgent care center (more than threefold increase; P\u00a0= .012) than patients with R\/RMM responding to CAR T-cell therapies. This was largely due to increased reports of mild upper respiratory tract infections in BsAb patients. Our results underscore the need to develop preemptive management strategies for commonly reported symptoms that patients with R\/RMM experience while receiving CAR T-cell or BsAb therapies. This preemptive management may significantly reduce unnecessary health care utilization in this vulnerable patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012871","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T20:56:02Z","timestamp":1713214562000},"page":"3246-3253","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies"],"prefix":"10.1182","volume":"8","author":[{"given":"Anna J.","family":"Howard","sequence":"first","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Concepcion","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice X.","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam S.","family":"Hamadeh","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn","family":"Tan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":false,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee H.","family":"Maclachlan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-286X","authenticated-orcid":false,"given":"Oscar B.","family":"Lahoud","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Chung","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-9320","authenticated-orcid":false,"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"10301","key":"2024062514453007600_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u00a0\u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicenter, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2024062514453007600_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024062514453007600_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2024062514453007600_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"24","key":"2024062514453007600_bib5","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2024062514453007600_bib6","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2024062514453007600_bib7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024062514453007600_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024062514453007600_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"2024062514453007600_bib10","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2024062514453007600_bib11","first-page":"308","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. transplant","volume":"30","author":"Dima","year":"2024","journal-title":"Cell Ther"},{"issue":"6","key":"2024062514453007600_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024062514453007600_bib13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/hematology.2023000434","article-title":"Current use of CAR T cells to treat multiple myeloma","volume":"2023","author":"Firestone","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2024062514453007600_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2024062514453007600_bib15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjh.19302","article-title":"Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: a real-world multicenter study","volume":"204","author":"Dima","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"2024062514453007600_bib16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"2024062514453007600_bib17","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: patient-reported outcomes in MajesTEC-1","volume":"40","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"S3","key":"2024062514453007600_bib18","doi-asserted-by":"crossref","first-page":"e690758f","DOI":"10.1097\/01.HS9.0000970820.69075.8f","article-title":"P979: patient-reported outcomes for listamab versus real-world physician\u2019s choice of therapy in the locommotion study in patients with triple-class exposed relapsed\/refractory multiple myeloma","volume":"7","author":"Moreau","year":"2023","journal-title":"HemaSphere"},{"issue":"8","key":"2024062514453007600_bib19","first-page":"917","article-title":"Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis","volume":"29","author":"Yang","year":"2023","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"4","key":"2024062514453007600_bib20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jha2.798","article-title":"Real-world utilization and healthcare costs for multiple myeloma: a retrospective analysis of patients in Singapore","volume":"4","author":"Bayani","year":"2023","journal-title":"EJHaem"},{"issue":"2","key":"2024062514453007600_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40487-023-00228-5","article-title":"Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma","volume":"11","author":"Jagannath","year":"2023","journal-title":"Oncol Ther"},{"issue":"7","key":"2024062514453007600_bib22","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"issue":"6","key":"2024062514453007600_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2024062514453007600_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2024062514453007600_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2022-165646","article-title":"Comprehensive characterization of prolonged unexplained cytopenias in relapsed\/refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy","volume":"140","author":"Thibaud","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2024062514453007600_bib26","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"issue":"Suppl 1","key":"2024062514453007600_bib27","doi-asserted-by":"crossref","first-page":"13085","DOI":"10.1182\/blood-2022-166879","article-title":"Improving quality of life and treatment adherence in multiple myeloma patients using education strategies based on digital and spaced learning","volume":"140","author":"Guio Oros","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024062514453007600_bib28","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2024062514453007600_bib29","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2022-167187","article-title":"Outpatient practice pattern for recently approved CAR-T in patients with lymphoma and multiple myeloma","volume":"140","author":"Bansal","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024062514453007600_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann","year":"1947","journal-title":"Ann Math Stat"},{"key":"2024062514453007600_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2105-7-123","article-title":"Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate","volume":"7","author":"Motulsky","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"19","key":"2024062514453007600_bib32","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"13","key":"2024062514453007600_bib33","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024062514453007600_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2024062514453007600_bib35","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1182\/blood-2022-163757","article-title":"Timing and nature of infections in multiple myeloma patients treated with anti-BCMA CAR-T cells","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2024062514453007600_bib36","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3246\/2232214\/blooda_adv-2024-012871-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3246\/2232214\/blooda_adv-2024-012871-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T14:46:57Z","timestamp":1719326817000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/12\/3246\/515754\/Unscheduled-health-care-interactions-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012871","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}